FDA Grants Breakthrough Therapy Designation to Seattle Genetics’ Adcetris in Frontline Advanced Hodgkin Lymphoma

BOTHELL, Wash.–(BUSINESS WIRE)–Oct. 2, 2017– Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma. The positive topline results of the phase 3 ECHELON-1 clinical trial were announced in June 2017 and full …

Original Article: FDA Grants Breakthrough Therapy Designation to Seattle Genetics’ Adcetris in Frontline Advanced Hodgkin Lymphoma

More From BioPortfolio on "FDA Grants Breakthrough Therapy Designation to Seattle Genetics’ Adcetris in Frontline Advanced Hodgkin Lymphoma"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications